Previous 10 | Next 10 |
2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...
I-Mab Signs Agreement to Divest its Assets and Business Operations in China PR Newswire Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus in advancing I-Mab's potential ...
I-Mab Announces Participation at Jefferies and Piper Conferences in November PR Newswire ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differe...
2023-11-02 10:07:57 ET More on I-Mab, Morphic, etc. Morphic Holding: The Price Drop Is Very Interesting I-Mab: Why This Company Trades At A Third The Value Of Its Cash I-Mab (IMAB) Q2 2023 Earnings Call Transcript MorphoSys expects a 5% surge in Monjuvi sales...
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) PR Newswire FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study ...
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 PR Newswire ROCKVILLE, MD , U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringi...
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 PR Newswire ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to ...
2023-10-15 07:15:00 ET Summary Suzhou MediLink Therapeutics out-licenses global rights for its HER3 antibody-drug conjugate candidate to BioNTech in a $1.1 billion deal. Beijing AI drug discovery company BioMap forms a strategic collaboration with Sanofi to co-develop new protein ...
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 PR Newswire - Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; ma...
2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...
News, Short Squeeze, Breakout and More Instantly...
I-MAB Company Name:
IMAB Stock Symbol:
NASDAQ Market:
I-MAB Filed 2023 Annual Report on Form 20-F PR Newswire ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of...
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercializa...
I-Mab Announces Closing of the Divestiture of Business Operations in China PR Newswire ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and ...